The addition of celecoxib improves the antitumor effect of cetuximab in colorectal cancer: role of EGFR-RAS-FOXM1-β-catenin signaling axis

Here we showed that the addition of the COX-2 inhibitor celecoxib improved the antitumor efficacy in colorectal cancer (CRC) of the monoclonal anti-EGFR antibody cetuximab. The addition of celecoxib augmented the efficacy of cetuximab to inhibit cell proliferation and to induce apoptosis in CRC cell...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Oncotarget
Päätekijät: Valverde, Araceli, Peñarando, Jon, Cañas, Amanda, López-Sánchez, Laura M., Conde, Francisco, Guil-Luna, Silvia, Hernández, Vanessa, Villar, Carlos, Morales-Estévez, Cristina, de la Haba-Rodríguez, Juan, Arand o, Enrique, Rodríguez-Ariza, Antonio
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Impact Journals LLC 2017
Aiheet:
Research Paper
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5400621/
https://ncbi.nlm.nih.gov/pubmed/28423516
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.15567
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia